ras GTPase inhibitor
Jump to navigation
Jump to search
Introduction
May be same as GAP-associated P62.
Function
- inhibition of H-ras-GTP GTPase activity enhanced 4 fold by diacylglycerol, 3-fold by 1-stearoyl,2-arachidonyl-phosphatidic acid, & 2-fold by arachidonate
- inhibition of H-ras-GTP GTPAse not stoichiometric.
Pharmacology
- ras GTPase family inhibitor adagrasib (Krazati) FDA approved for treatment of non-small cell lung carcinoma (NSCLC)
More general terms
References
- ↑ Food and Drug Administration (FDA) December 12, 2022 FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-kras-g12c-mutated-nsclc